The Bio Products Laboratory (BPL) Global Medical Publications team expects a record year in 2022, with more scientific abstracts, posters, and manuscripts submitted or presented than in any year in the company’s history.
The BPL Global Medical Publications Team expects a record year in 2022
23 June 2022
BPL Featured in Manufacturing Today
20 June 2022
Bio Products Laboratory (BPL), a leading manufacturer in plasma-derived protein therapies, is pleased to share that we have been featured in the May Edition of Manufacturing Today.
BPL Celebrates World Blood Donor Day
14 June 2022
Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today celebrates World Blood Donor Day. The annual event serves to raise awareness of the importance of donating blood and the need for safe blood and blood products. The day is also an opportunity to thank all blood donors across the world.
BPL expands options for patients in the Dominican Republic with marketing authorization for Coagadex®
01 June 2022
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today the issuance of a marketing authorization for Coagadex® in the Dominican Republic.
BPL receives orphan drug marketing authorization for Coagadex® in Mexico
04 May 2022
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today it has received orphan drug marketing authorization for Coagadex® in Mexico.
BPL Plasma opens its 29th donor centre
22 April 2022
Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, are pleased to announce that on 22 April, BPL Plasma opened its 29th plasma donation centre.
BPL Celebrates World Hemophilia Day 2022
17 April 2022
Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, joins the global bleeding disorders community in recognition of World Hemophilia Day (WHD). Observed annually on 17 April, WHD honours Frank Schnabel’s birthday, a person who suffered from severe hemophilia, and subsequently established the World Federation of Hemophilia (WFH).
BPL Marks Bleeding Disorders Awareness Month 2022
31 March 2022
Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today marks the end of Bleeding Disorders Awareness Month1. Recognised every March, this month aims to help raise awareness of inheritable blood and bleeding disorders and the 300 million people affected by them worldwide.
BPL granted a new patent in the US
30 March 2022
The United States Patent and Trademark Office granted a new patent (US Patent number: 11,149,079) to BPL for its ‘E+I’ process, granted in the US.